Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -

NCT00338936 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00338936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
September 30, 2007
Enrollment
362 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension